New York State Common Retirement Fund Has $40.78 Million Holdings in Glaukos Co. (NYSE:GKOS)

New York State Common Retirement Fund boosted its holdings in Glaukos Co. (NYSE:GKOS) by 0.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 513,029 shares of the medical instruments supplier’s stock after buying an additional 1,867 shares during the quarter. New York State Common Retirement Fund owned approximately 1.05% of Glaukos worth $40,781,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of GKOS. CWM LLC boosted its stake in Glaukos by 309.5% in the third quarter. CWM LLC now owns 1,384 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 1,046 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Glaukos by 17.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier’s stock valued at $137,000 after buying an additional 270 shares in the last quarter. Mackenzie Financial Corp acquired a new stake in Glaukos in the third quarter valued at about $203,000. Xponance Inc. acquired a new stake in shares of Glaukos during the third quarter valued at about $208,000. Finally, Pathstone Family Office LLC acquired a new stake in shares of Glaukos during the third quarter valued at about $217,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

GKOS has been the topic of a number of recent research reports. StockNews.com lowered Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, February 27th. Stifel Nicolaus reissued a “buy” rating and set a $110.00 price target on shares of Glaukos in a research note on Wednesday, April 3rd. Truist Financial reissued a “buy” rating and set a $110.00 price target on shares of Glaukos in a research note on Monday, April 8th. Wells Fargo & Company raised their price objective on Glaukos from $83.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, February 22nd. Finally, Needham & Company LLC raised their price objective on Glaukos from $105.00 to $108.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $99.80.

Insiders Place Their Bets

In other Glaukos news, COO Joseph E. Gilliam sold 9,476 shares of Glaukos stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $94.12, for a total value of $891,881.12. Following the completion of the sale, the chief operating officer now directly owns 119,802 shares in the company, valued at $11,275,764.24. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Mark J. Foley sold 4,560 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $92.87, for a total transaction of $423,487.20. Following the completion of the sale, the director now owns 33,220 shares in the company, valued at $3,085,141.40. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Joseph E. Gilliam sold 9,476 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $94.12, for a total value of $891,881.12. Following the sale, the chief operating officer now owns 119,802 shares of the company’s stock, valued at approximately $11,275,764.24. The disclosure for this sale can be found here. Over the last three months, insiders sold 242,357 shares of company stock worth $22,857,372. 6.40% of the stock is owned by corporate insiders.

Glaukos Price Performance

Shares of GKOS stock opened at $101.03 on Thursday. The stock has a 50 day simple moving average of $92.08 and a two-hundred day simple moving average of $81.28. The company has a current ratio of 5.34, a quick ratio of 4.78 and a debt-to-equity ratio of 0.77. Glaukos Co. has a fifty-two week low of $45.38 and a fifty-two week high of $103.66.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). The business had revenue of $82.40 million during the quarter, compared to the consensus estimate of $81.00 million. Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The company’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.53) earnings per share. As a group, analysts forecast that Glaukos Co. will post -2.18 earnings per share for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.